The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

so FDA approval will lead to a safer, more well-regulated control and use of this medication in clinical practice for patients with major depressive disorder.” “Given the reality that ...

Also Read: Neurocrine’s Drug Gains FDA Nod As First Targeted Treatment ... which are being studied for the treatment of major depressive disorder, as well as a preclinical GPR139 antagonist ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Major depressive disorder (MDD) is a chronic and recurrent ... Eventually, in November 2007, aripiprazole was the first approved by the US FDA as an adjunctive treatment to antidepressants for ...